Literature DB >> 25792004

Post-operative stimulated thyroglobulin and neck ultrasound as personalized criteria for risk stratification and radioactive iodine selection in low- and intermediate-risk papillary thyroid cancer.

Steven Orlov1, Farnaz Salari, Lawrence Kashat, Jeremy L Freeman, Allan Vescan, Ian J Witterick, Paul G Walfish.   

Abstract

The purpose of this study was to demonstrate the utility of a personalized risk stratification and radioactive iodine (RAI) selection protocol (PRSP) using post-operative stimulated thyroglobulin (Stim-Tg) and neck ultrasound in low- and intermediate-risk papillary thyroid carcinoma (PTC) patients. Patients with PTC tumors ≥1 cm were prospectively followed after total thyroidectomy and selective therapeutic central compartment neck dissection. Low/intermediate risk was defined as PTC confined to the thyroid or central (level VI) lymph nodes. Stim-Tg and neck ultrasound were performed approximately 3 months after surgery and used to guide RAI selection. Patients with Stim-Tg < 1 µg/L did not receive RAI, while those with Stim-Tg >5 µg/L routinely did. Those with Stim-Tg 1-5 µg/L received RAI on the basis of several clinical risk factors. Patients were followed for >6 years with serial neck ultrasound and basal/stimulated thyroglobulin. Among the 129 patients, 84 (65 %) had undetectable Stim-Tg after initial surgery, 40 (31 %) had Stim-Tg of 1-5 µg/L, and 5 (4 %) had Stim-Tg >5 µg/L. RAI was administered to 8 (20 %) patients with Stim-Tg 1-5 µg/L and 5 (100 %) with Stim-Tg >5 µg/L. Using this approach, RAI therapy was avoided in 17/20 (85 %) patients with tumors >4 cm, in 72/81 (89 %) patients older than 45 years, and in 6/9 (67 %) patients with central lymph node involvement. To date, 116 (90 %) patients in this cohort have not received RAI therapy with no evidence of residual/recurrent disease, whereas among the 13 patients who received RAI, 1 (8 %) had pathologic residual/recurrence disease. Using the proposed PRSP, RAI can be avoided in the majority of low/intermediate-risk PTC patients. Moreover, traditional risk factors considered to favor RAI treatment were not always concordant with the PRSP and may lead to overtreatment.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25792004     DOI: 10.1007/s12020-015-0575-0

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  27 in total

1.  Use of recombinant thyrotropin.

Authors:  Anthony Toft; Geoffrey Beckett
Journal:  Lancet       Date:  2002-06-01       Impact factor: 79.321

2.  Stimulated thyroglobulin and neck ultrasonography facilitates postsurgical radioactive iodine remnant ablation selection in patients with low-risk well-differentiated thyroid carcinoma.

Authors:  Karen Gomez Hernandez; Daniel Etarsky; Steven Orlov; Paul G Walfish
Journal:  Thyroid       Date:  2012-06-04       Impact factor: 6.568

3.  Predictive value of metastatic cervical lymph node ratio in papillary thyroid carcinoma recurrence.

Authors:  Jonathan Yip; Steven Orlov; David Orlov; Alon Vaisman; Karen Gómez Hernández; Daniel Etarsky; Ipshita Kak; Nikoo Parvinnejad; Jeremy L Freeman; Paul G Walfish
Journal:  Head Neck       Date:  2012-06-23       Impact factor: 3.147

4.  Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma.

Authors:  Karen A Heemstra; Ying Y Liu; Marcel Stokkel; Job Kievit; Eleonora Corssmit; Alberto M Pereira; Johannes A Romijn; Johannes W A Smit
Journal:  Clin Endocrinol (Oxf)       Date:  2007-01       Impact factor: 3.478

5.  Prognostic value of postsurgical stimulated thyroglobulin levels after initial radioactive iodine therapy in well-differentiated thyroid carcinoma.

Authors:  Anna M Sawka; Steven Orlov; Jacob Gelberg; Barry Stork; Mark Dowar; Michael Shaytzag; Vafa Tabatabaie; Jeremy L Freeman; Paul G Walfish
Journal:  Head Neck       Date:  2008-06       Impact factor: 3.147

6.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

7.  Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma.

Authors:  Alon Vaisman; Steven Orlov; Jonathan Yip; Cindy Hu; Terence Lim; Mark Dowar; Jeremy L Freeman; Paul G Walfish
Journal:  Head Neck       Date:  2010-06       Impact factor: 3.147

8.  A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later.

Authors:  Richard T Kloos; Ernest L Mazzaferri
Journal:  J Clin Endocrinol Metab       Date:  2005-06-21       Impact factor: 5.958

9.  Value of postoperative thyroglobulin and ultrasonography for the indication of ablation and ¹³¹I activity in patients with thyroid cancer and low risk of recurrence.

Authors:  Pedro Weslley Rosario; Arthur Cezar Malard Xavier; Maria Regina Calsolari
Journal:  Thyroid       Date:  2010-10-18       Impact factor: 6.568

10.  Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer.

Authors:  A Iervasi; G Iervasi; M Ferdeghini; C Solimeo; A Bottoni; L Rossi; C Colato; G C Zucchelli
Journal:  Clin Endocrinol (Oxf)       Date:  2007-06-06       Impact factor: 3.478

View more
  11 in total

Review 1.  Controversies in the Management of Low-Risk Differentiated Thyroid Cancer.

Authors:  Megan R Haymart; Nazanene H Esfandiari; Michael T Stang; Julia Ann Sosa
Journal:  Endocr Rev       Date:  2017-08-01       Impact factor: 19.871

2.  Is TSH suppression still necessary in intermediate- and high-risk papillary thyroid cancer patients with pre-ablation stimulated thyroglobulin <1 ng/mL before the first disease assessment?

Authors:  Tian Tian; Rui Huang; Bin Liu
Journal:  Endocrine       Date:  2019-03-28       Impact factor: 3.633

3.  Serial post-surgical stimulated and unstimulated highly sensitive thyroglobulin measurements in low- and intermediate-risk papillary thyroid carcinoma patients not receiving radioactive iodine.

Authors:  Lawrence Kashat; Steven Orlov; David Orlov; Jasmeet Assi; Farnaz Salari; Paul G Walfish
Journal:  Endocrine       Date:  2016-05-17       Impact factor: 3.633

4.  Papillary thyroid carcinomas with biochemical incomplete or indeterminate responses to initial treatment: repeat stimulated thyroglobulin assay to identify disease-free patients.

Authors:  Livia Lamartina; Teresa Montesano; Fabiana Trulli; Marco Attard; Massimo Torlontano; Rocco Bruno; Domenico Meringolo; Fabio Monzani; Salvatore Tumino; Giuseppe Ronga; Marianna Maranghi; Marco Biffoni; Sebastiano Filetti; Cosimo Durante
Journal:  Endocrine       Date:  2015-12-14       Impact factor: 3.633

5.  Iodine-131: An Effective Method for Treating Lymph Node Metastases of Differentiated Thyroid Cancer.

Authors:  Ying He; Ming-Zhi Pan; Jian-Min Huang; Peng Xie; Fang Zhang; Ling-Ge Wei
Journal:  Med Sci Monit       Date:  2016-12-15

6.  Dynamic monitoring of circulating microRNAs as a predictive biomarker for the diagnosis and recurrence of papillary thyroid carcinoma.

Authors:  Yanqing Zhang; Desheng Xu; Jiaqi Pan; Zhengkai Yang; Meijun Chen; Jun Han; Sijia Zhang; Lulu Sun; Hong Qiao
Journal:  Oncol Lett       Date:  2017-04-11       Impact factor: 2.967

7.  The Prognostic Role of Postablative Non-Stimulated Thyroglobulin in Differentiated Thyroid Cancer.

Authors:  Szabina Szujo; Laszlo Bajnok; Beata Bodis; Zsuzsanna Nagy; Orsolya Nemes; Karoly Rucz; Emese Mezosi
Journal:  Cancers (Basel)       Date:  2021-01-15       Impact factor: 6.639

Review 8.  Differentiated Thyroid Cancer: A Health Economic Review.

Authors:  Klaas Van Den Heede; Neil S Tolley; Aimee N Di Marco; Fausto F Palazzo
Journal:  Cancers (Basel)       Date:  2021-05-07       Impact factor: 6.639

Review 9.  Risk Stratification in Differentiated Thyroid Cancer: An Ongoing Process.

Authors:  Gal Omry-Orbach
Journal:  Rambam Maimonides Med J       Date:  2016-01-28

10.  Role of Preablative Stimulated Thyroglobulin in Prediction of Nodal and Distant Metastasis on Iodine Whole-Body Scan.

Authors:  Meghana Prabhu; Sanju Samson; Avinash Reddy; Sunil Hejaji Venkataramanarao; Naveen Hedne Chandrasekhar; Vijay Pillai; Vivek Shetty; Moni Abraham Koriokose; Bushan Vaidhya; Subramanian Kannan
Journal:  Indian J Nucl Med       Date:  2018 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.